RXi Pharmaceuticals said this week that it has closed its acquisition of peptide immunotherapy firm Apthera.
As previously announced, RXi bought the firm for around $7.2 million in order to accelerate its move from a research-based company to a clinical-stage one (GSN 3/31/2011). Among Apthera's assets is the phase II breast cancer treatment NeuVax.